Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 65

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 65
---
 from known molecules with strong scientific rationale, and also by re -definingpreviously approved molecules with well -establishedtolerability and safety profiles, as determined by applicable regulatory agencies. NLS believes that its streamlined clinical development approach has the potential to advance its product candidates rapidly through early -stageclinical trials, while carrying an overall lower development risk. A lower development risk, NLS believes, exists with respect to the development of its lead product candidate, Quilience, and follow -onproduct candidate, Nolazol, due to their use of mazindol as the active ingredient, which was previously approved and marketed in the United States, Japan and Europe to manage exogenous obesity (obesity caused by overeating). The Merger Agreement provides that, upon the terms and subject to the conditions thereof, following the Closing, NLS shall work diligently to dispose of any Legacy Assets, which excludes the DOXA platform. The DOXA platform includes AEX -041. It is important to note that AEX -041is currently in the preclinical stage of development. This means that the candidate is undergoing early laboratory studies to evaluate its safety profile and pharmacological properties, and it has not yet been tested in human clinical trials. Consequently, its efficacy, safety, and potential for regulatory approval remain subject to further research and development. NLS was incorporated on June 10, 2015, as a Swiss limited company. NLS’s registered office and principal executive offices are located at The Circle6, 8058 Zurich, Switzerland. NLS’s telephone number in Switzerland is +41.44.512.2150 and its website address is https://nlspharma.com. The information contained on, or that can be accessed through, NLS’s website is not part of this proxy statement/prospectus. The website address has been included in this proxy statement/prospectus solely as an inactive textual reference. After the consummation of the Merger, NLS’s principal executive office will remain at The Circle6, 8058 Zurich, Switzerland, Tel: +41.44.512.2150. Merger Sub Merger Sub was incorporated on November 3, 2024, under the laws of the State of Israel, as a wholly -ownedsubsidiary of NLS for the purpose of effecting the Merger and to serve as the vehicle for, and to be subsumed by, Kadimastem pursuant to the Merger. 1 Kadimastem Kadim